Core Insights - Cencora reported a revenue of $85.9 billion for the first quarter of fiscal 2026, marking a 5.5% increase year-over-year, driven by growth in both U.S. and International Healthcare Solutions segments [1][2] - The company achieved a GAAP diluted EPS of $2.87, up 14.8% from $2.50 in the prior year, while adjusted diluted EPS rose 9.4% to $4.08 [1][3] - Cencora raised its adjusted operating income guidance for fiscal 2026 to a growth range of 11.5% to 13.5%, reflecting the acquisition of OneOncology and strong performance in the U.S. Healthcare Solutions segment [1][2] Financial Performance - Revenue for the U.S. Healthcare Solutions segment was $76.2 billion, a 5.0% increase year-over-year, attributed to market growth and increased sales of specialty products [2] - International Healthcare Solutions segment revenue reached $7.6 billion, up 9.6% year-over-year, primarily due to growth in the European distribution business [2] - Operating income for the U.S. Healthcare Solutions segment increased by 21.0% to $831.3 million, while the International Healthcare Solutions segment saw a decrease of 13.9% in operating income to $142.2 million [2] Segment Analysis - The U.S. Healthcare Solutions segment's growth was driven by unit volume growth and increased sales of diabetes and weight loss products, despite some losses from specific customers [2] - The International Healthcare Solutions segment's revenue growth was 6.2% on a constant currency basis, but operating income decreased by 17.0% due to challenges in the European distribution business [2] - Revenue from other businesses, including MWI Animal Health and Profarma, was $2.1 billion, reflecting a 6.3% increase, although operating income in this category decreased by 6.1% [2] Guidance and Expectations - Cencora reaffirmed its full fiscal 2026 adjusted diluted EPS guidance range of $17.45 to $17.75, reflecting the expected contributions from the OneOncology acquisition [2] - The company anticipates revenue growth of 7% to 9% across its segments, with adjusted operating income growth projected at 11.5% to 13.5% [2] - The adjusted effective tax rate is expected to be around 20% for fiscal 2026, with net interest expense projected between $480 million and $500 million [2]